Leveraging Parvovirus Vectors to Combat Immunogenicity, Off-Target Effects, & Limited Payload Capacity
Time: 2:00 pm
day: Conference Day Two
Details:
- Highlighting how selecting a vector with limited pre-existing human immunity and excellent tissue tropism improves vector efficacy and safety
- Exploring the benefits of additional cargo space to treat a wider range of indications
- Consolidating learnings and regulations from AAV vectors to facilitate parvovirus vector development
